Condition (MeSH)
Bicuspid Aortic Valve Disease
ClinicalTrials.gov lists 62 trials for Bicuspid Aortic Valve Disease or a narrower condition beneath it. Solventum US LLC has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
62 of the 62 trials are tagged with Bicuspid Aortic Valve Disease itself; the rest are tagged with a narrower condition beneath it.
When did Bicuspid Aortic Valve Disease trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 6 |
| 2024 | 4 |
| 2023 | 7 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 3 |
| 2019 | 4 |
| 2018 | 5 |
| 2016 | 6 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 32 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Bicuspid Aortic Valve Disease trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 19 |
| Observational | 38 |
How many Bicuspid Aortic Valve Disease trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 16 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 6 |
| Completed | 28 |
| Terminated | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Bicuspid Aortic Valve Disease trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Solventum US LLC | 2 |
| China National Center for Cardiovascular Diseases | 1 |
Which drugs are being tested for Bicuspid Aortic Valve Disease? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| TACE | 1 |
| ATORVASTATIN | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| No Interventions | 1 |
| additional tissue samples | 1 |
| Low dose losartan | 1 |
| Telmisartan 80 | 1 |
| Atenolol Pill | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Bicuspid Aortic Valve Disease trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Atrioventricular Block Complete | 13 | 1 |
| Hypotension | 7 | 1 |
| Bundle Branch Block Left | 5 | 1 |
| Unexpected Serious Adverse Event | 5 | 1 |
| Atrial Fibrillation | 4 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Bicuspid Aortic Valve Disease? (77)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Contribution of rare chromosome 22q11.2 copy number variants to non-syndromic bicuspid aortic valve. | Heart (British Cardiac Society) | 2025 | Yes |
| Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial. | Circulation | 2024 | Yes |
| Bicuspid valve repair outcomes are improved with reduction and stabilization of sinotubular junction and annulus with external annuloplasty. | The Journal of thoracic and cardiovascular surgery | 2024 | Yes |
| Five-Year Outcomes After Bicuspid Aortic Valve Replacement With a Novel Tissue Bioprosthesis. | The Annals of thoracic surgery | 2024 | Yes |
| Comparison of downsizing strategy (HANGZHOU Solution) and standard annulus sizing strategy in type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement: Rationale and design of a randomized clinical trial. | American heart journal | 2024 | Yes |
Showing 5 of 77 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.